Download PDF

1. Company Snapshot

1.a. Company Description

Pfizer Inc.discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.


The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands.In addition, the company is involved in the contract manufacturing business.It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers.


The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc.Pfizer Inc.was founded in 1849 and is headquartered in New York, New York.

Show Full description

1.b. Last Insights on PFE

Pfizer's recent performance is driven by several positive factors. The company's Q2 earnings beat estimates, with a 36% EPS beat, driven by aggressive cost-cutting and a strong non-COVID portfolio, led by oncology and rare disease drugs. A direct-to-consumer deal and a three-year tariff reprieve also contributed to the positive momentum. Additionally, a landmark drug-pricing deal with the US government may present further upside potential. The company's dividend is considered safe, with a high yield of 6.28% and a forward PE of 8.87. Institutional investors are also showing strong buying interest.

1.c. Company Highlights

2. Pfizer's Q3 2025 Earnings: A Closer Look

Pfizer reported revenues of $16.7 billion for the third quarter of 2025, a 7% decline operationally compared to the same period last year, primarily due to a decline in COVID products. However, non-COVID products showed a 4% operational growth, driven by strong performances from Eliquis, the Vyndaqel family, and Nurtec. Adjusted gross margin was approximately 76%, reflecting the product mix and continued cost management. Adjusted diluted EPS came in at $0.87, beating estimates of $0.633.

Publication Date: Nov -05

📋 Highlights
  • Q3 Revenue Decline:: Total revenue fell to $16.7B, a 7% operational decrease YoY, primarily due to declining COVID product sales.
  • Non-COVID Growth:: Non-COVID products grew 4% operationally, contributing $7.3B in revenue from new/late-stage products in the first 9 months of 2025.
  • Metsera Acquisition Impact:: $4.9B deal expected to dilute 2026 adjusted EPS by $0.16, with an additional $0.05 dilution from 3SBio integration.
  • Cost Savings & Margin Expansion:: $1.5B savings from manufacturing optimization by 2027 and $500M R&D efficiency by 2026, reinvested into pipelines.
  • Shareholder Returns:: $7.3B returned to shareholders via dividends in 9M 2025, while retaining $7.2B in R&D investment for pipeline growth.

Segment Performance

The company's vaccines portfolio, particularly the Prevnar family, demonstrated strong international growth, with a 17% year-over-year increase. Pfizer's R&D infrastructure and commercial capabilities position it well for future growth, especially with the proposed acquisition of Metsera, which is expected to advance innovation in the obesity therapeutic area.

COVID-19 Products and Guidance

COVID-19 products saw a decline due to lower vaccination rates and infection rates. Despite this, Pfizer maintained its full-year 2025 revenue guidance range of $61 billion to $64 billion. The company raised its adjusted diluted EPS guidance to $3.00 to $3.15 per share, indicating confidence in its non-COVID products and cost management.

Valuation and Dividend

With a P/E Ratio of 14.07 and a Dividend Yield of 7.04%, Pfizer's valuation suggests a relatively stable outlook. The company's ability to maintain and grow its dividend, alongside its commitment to R&D, positions it for long-term growth. Pfizer's capital allocation strategy includes reinvesting in the business and making value-enhancing share repurchases, although the latter is not a near-term priority.

Future Prospects

Pfizer's acquisition of Metsera and its ongoing R&D efforts, including the 25-valent pneumococcal program, indicate a strong pipeline. The company's focus on operational efficiencies and cost savings is expected to drive future performance. With a Net Debt / EBITDA ratio of 2.85, Pfizer has a manageable debt position, and its ROIC of 10.65% suggests effective capital utilization.

3. NewsRoom

Card image cap

Market Today: WBD Sale Bids, Meta Cuts, Apple Shake-Up

Dec -04

Source: gurufocus.com

Card image cap

Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (December 2025)

Dec -04

Source: 247wallst.com

Card image cap

First Look: Insurers, Auto Rules, AI and Fed Jitters

Dec -04

Source: gurufocus.com

Card image cap

3 Potential Mid-Cap Biotech Buyout Targets In 2026

Dec -03

Source: seekingalpha.com

Card image cap

17 dividend-stock bargains from a value manager with a stellar track record

Dec -02

Source: marketwatch.com

Card image cap

Pfizer's Cancer Drugs Deliver Growth Amid Competitive Pressure

Dec -02

Source: zacks.com

Card image cap

Beacon Pointe Advisors LLC Sells 607,423 Shares of Pfizer Inc. $PFE

Dec -02

Source: defenseworld.net

Card image cap

Dow Jones Today: Stock Indexes Close Lower to Begin December Trading; Big Tech, Crypto-Tied Shares Drop Amid Risk-Off Sentiment

Dec -02

Source: investopedia.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (7.85%)

6. Segments

Global Biopharmaceuticals Business (Biopharma)

Expected Growth: 7.9%

Pfizer's Biopharma segment is driven by the increasing demand for innovative medicines and a strong pipeline of oncology and inflammation products, which is expected to contribute significantly to the company's growth.

Pfizer Centreone (pc1)

Expected Growth: 5.2%

None

Pfizer Ignite

Expected Growth: 7.5%

Pfizer Ignite accelerates biomedical innovations, driving growth through strategic investments, partnerships, and talent acquisition, positioning Pfizer Inc. for strong market growth

7. Detailed Products

Comirnaty

COVID-19 vaccine

Ibrance

Cancer treatment

Xeljanz

Rheumatoid arthritis treatment

Viagra

Erectile dysfunction treatment

Chantix

Smoking cessation treatment

Lyrica

Pain management treatment

Prevnar 13

Pneumococcal conjugate vaccine

Xalkori

Cancer treatment

Sutent

Cancer treatment

8. Pfizer Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Pfizer Inc. has a moderate threat of substitutes due to the presence of alternative treatments and generic drugs in the market.

Bargaining Power Of Customers

Pfizer Inc. has a low bargaining power of customers due to the lack of negotiating power of individual customers in the pharmaceutical industry.

Bargaining Power Of Suppliers

Pfizer Inc. has a moderate bargaining power of suppliers due to the presence of multiple suppliers of raw materials and services.

Threat Of New Entrants

Pfizer Inc. has a low threat of new entrants due to the high barriers to entry in the pharmaceutical industry, including high research and development costs and regulatory hurdles.

Intensity Of Rivalry

Pfizer Inc. operates in a highly competitive industry with many established players, leading to a high intensity of rivalry among competitors.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 44.86%
Debt Cost 3.95%
Equity Weight 55.14%
Equity Cost 6.86%
WACC 5.55%
Leverage 81.35%

11. Quality Control: Pfizer Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Gilead Sciences

A-Score: 6.5/10

Value: 3.3

Growth: 3.0

Quality: 8.6

Yield: 7.0

Momentum: 9.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Pfizer

A-Score: 6.1/10

Value: 6.1

Growth: 2.9

Quality: 6.7

Yield: 9.0

Momentum: 3.5

Volatility: 8.7

1-Year Total Return ->

View Full Report
Stock-Card
Merck

A-Score: 5.9/10

Value: 4.8

Growth: 6.2

Quality: 7.8

Yield: 7.0

Momentum: 1.5

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Bristol-Myers Squibb

A-Score: 5.6/10

Value: 5.0

Growth: 3.9

Quality: 6.4

Yield: 8.0

Momentum: 2.0

Volatility: 8.3

1-Year Total Return ->

View Full Report
Stock-Card
Lilly

A-Score: 4.4/10

Value: 2.0

Growth: 7.2

Quality: 6.9

Yield: 2.0

Momentum: 2.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Biogen

A-Score: 4.2/10

Value: 6.3

Growth: 3.0

Quality: 7.6

Yield: 0.0

Momentum: 1.0

Volatility: 7.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

26.03$

Current Price

26.03$

Potential

-0.00%

Expected Cash-Flows